Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1519

U31784-hIgG1

Home » Antibodies » U31784-hIgG1

Background of U31784-hIgG1

Fibroblast Growth Factor Receptor 4 (FGFR4) is the fourth member of the FGF tyrosine kinase receptor family, which regulates cellular pathways involved in proliferation, differentiation, and survival. Fibroblast Growth Factor 19 (FGF19), a natural ligand for FGFR4, exhibits unique specificity for this receptor and plays a crucial role in regulating bile acid synthesis and hepatocyte proliferation in the normal liver. U3-1784 is a fully human IgG1 monoclonal antibody and an antagonist to the FGF19 ligand. It selectively targets FGFR4 without binding to FGFR1, FGFR2, or FGFR3, making it a promising therapeutic agent for conditions driven by the FGF19/FGFR4 pathway.

Specifications

Catalog Number:
KB-1519
Antibody Name:
U31784-hIgG1
Isotype:
Human IgG1,lambda
FC Muations:
Target:
FGFR4
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity.
  2. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma